Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.

Nissen, Steven E; Wolski, Kathy; Balog, Craig; Swerdlow, Daniel I; Scrimgeour, Alison C; Rambaran, Curtis; Wilson, Rosamund J; Boyce, Malcom; Ray, Kausik K; Cho, Leslie; Watts, Gerald F; Koren, Michael; Turner, Traci; Stroes, Erik S; Melgaard, Carrie; Campion, Giles V

Nissen, Steven E; Wolski, Kathy; Balog, Craig; Swerdlow, Daniel I; Scrimgeour, Alison C; Rambaran, Curtis; Wilson, Rosamund J; Boyce, Malcom; Ray, Kausik K; Cho, Leslie; Watts, Gerald F; Koren, Michael; Turner, Traci; Stroes, Erik S; Melgaard, Carrie; Campion, Giles V.

Affiliation

Nissen SE; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
Wolski K; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
Balog C; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
Swerdlow DI; Silence Therapeutics PLC, London, England.
Scrimgeour AC; Silence Therapeutics PLC, London, England.
Rambaran C; Silence Therapeutics PLC, London, England.
Wilson RJ; Spica Consultants Ltd, Marlborough, England.
Boyce M; UK Hammersmith Medicines Research, London, England.
Ray KK; Imperial College London, London, England.
Cho L; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
Watts GF; Royal Perth Hospital and School of Medicine, Departments of Cardiology and Internal Medicine, University of Western Australia, Perth, Australia.
Koren M; Jacksonville Center for Clinical Research, Jacksonville, Florida.
Turner T; Medpace, Cincinnati, Ohio.
Stroes ES; Faculty of Medicine, University of Amsterdam, Amsterdam, the Netherlands.
Melgaard C; Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
Campion GV; Silence Therapeutics PLC, London, England.

JAMA ; 327(17): 1679-1687, 2022 05 03.

Article in En | MEDLINE | ID: mdl-35368052

Subject(s)

Apoprotein(a); Hyperlipoproteinemias; RNA, Small Interfering; Adult; Apoprotein(a)/adverse effects; Apoprotein(a)/biosynthesis; Apoprotein(a)/blood; Cardiovascular Diseases/etiology; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperlipoproteinemias/blood; Hyperlipoproteinemias/genetics; Hyperlipoproteinemias/metabolism; Hyperlipoproteinemias/therapy; Injections, Subcutaneous; Lipoprotein(a)/adverse effects; Lipoprotein(a)/biosynthesis; Lipoprotein(a)/blood; Male; Middle Aged; RNA, Small Interfering/administration & dosage; RNA, Small Interfering/adverse effects; RNA, Small Interfering/therapeutic use; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Small Interfering / Apoprotein(a) / Hyperlipoproteinemias Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google